Abstract

Research Article

The SARS CoV-2 spike domain, RGD and integrin binding effect-relationship for vaccine design strategy

Luisetto M*, Tarro G, Khaled Edbey, Almukthar N, Cabianca L, Mashori GR, Ahnaf Ilman, Yesvi AR and Latyschev OY

Published: 20 July, 2021 | Volume 5 - Issue 1 | Pages: 027-041

Related the need to search new strategy in vaccine design in order to reduce also some rare effect like trombosys for some registered products it is interesting the role played by the SPIKE RGD domain.

The binding with molecules like Fibronectin is a process that must to be deeply investigated.

A better understanding in this process can be used to improve safety of the new generation of COVID vaccine.

The rare effect like thrombosis recognized by regulatory agency produced a modification of technical data sheet of some vaccine so the phenomena Is interesting to be more investigated.

Spike protein and its domains are involved in producing pathological effect of the COVID-19 disease.

What it is interesting is that some pathological effect of this pathology are similar to some rare side effect produced by some COVID-19 vaccine classes.

After a review of interesting literature related this topics is submitted an experimental projects able to verify in vitro the spike procoaugulant property.

Read Full Article HTML DOI: 10.29328/journal.apb.1001014 Cite this Article Read Full Article PDF

Keywords:

SARS CoV-2; Spike domain; RGD; Integrin; Fibronectin; Protrombotic; Vaccine design strategy; Second generation COVID Vaccine

References

  1. Shulla A, Gallagher T. Role of Spike Protein Endodomains in Regulating Coronavirus Entry. Protein Struct Fold. 2009; 284: 32725-32734. PubMed: https://pubmed.ncbi.nlm.nih.gov/19801669/
  2. Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19.
  3. Janardhan V, Janardhan V, Kalousek V. COVID-19 as a Blood Clotting Disorder Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic Implications for Stroke Thrombectomy. J Neuroimaging. 2020; 30: 555-561. PubMed: https://pubmed.ncbi.nlm.nih.gov/32776617/
  4. Makowski L, Olson-Sidford W, Weisel J. Biological and Clinical Consequencesof Integrin Binding via a Rogue RGDMotif in the SARS CoV-2 Spike. Protein. Viruses. 2021; 13: 146. PubMed: https://pubmed.ncbi.nlm.nih.gov/33498225/
  5. Carvacho I, Piesche M. RGD‐binding integrins and TGF‐β in SARS‐CoV‐2 infections – novel targets to treat COVID‐19 patients? Clin Transl Immunol. 2021; 10: e1240. PubMed: https://pubmed.ncbi.nlm.nih.gov/33747508/
  6. Park EJ, Myint PK, Appiah MG, Darkwah S, Caidengbate S, et al. The Spike Glycoprotein of SARS-CoV-2 Binds to β1 Integrins Expressed on the Surface of Lung Epithelial Cells. Viruses. 2021; 13: 645. PubMed: https://pubmed.ncbi.nlm.nih.gov/33918599/
  7. Yang J, Wang W, Chen Z, Lu S, Yang F, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020; 586: 572–577. PubMed: https://pubmed.ncbi.nlm.nih.gov/32726802/
  8. Prompetchara E, Ketloy C, Tharakhet K, Kaewpang P, Buranapraditkun S, et al. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS One 2021; 16: e0248007. PubMed: https://pubmed.ncbi.nlm.nih.gov/33750975/
  9. Du L, He Y, Zhou Y, Liu S, Zheng BJ, et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7: 226–236. PubMed: https://pubmed.ncbi.nlm.nih.gov/19198616/
  10. Buonvino S, Melino S. New Consensus pattern in Spike CoV-2: potential implications in coagulation process and cell–cell fusion. Cell Death Discovery. 2020; 6: 134.
  11. Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020; 370: 1089-1094. PubMed: https://pubmed.ncbi.nlm.nih.gov/33082295/
  12. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020; 173: 268-277. PubMed: https://pubmed.ncbi.nlm.nih.gov/32374815/
  13. Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clotthickens! Eur Respir J. 2020; 56: 2001608. PubMed: https://pubmed.ncbi.nlm.nih.gov/32554532/
  14. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288: 198114. PubMed: https://pubmed.ncbi.nlm.nih.gov/32800805/
  15. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020; 14: 12522-12537. PubMed: https://pubmed.ncbi.nlm.nih.gov/33034449/
  16. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, et al. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens ront Immunol. 2020; 11: 576622. PubMed: https://pubmed.ncbi.nlm.nih.gov/33117378/
  17. Xia X, Lundstrom K, Alaa AA. Aljabali. Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design. Viruses. 2021; 13: 109. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829931/
  18. Kamel MH, Yin W, Zavaro C, Francis JM, Chitalia VC. Cells Review Hyperthrombotic Milieu in COVID-19 Patients. Cells. 2020 31; 9: 2392. PubMed: https://pubmed.ncbi.nlm.nih.gov/33142844/
  19. Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021; 137: 111254. PubMed: https://pubmed.ncbi.nlm.nih.gov/33550049/
  20. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021; 21: 73–82. PubMed: https://pubmed.ncbi.nlm.nih.gov/33340022/
  21. Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, et al. Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19. Circ Res. 2020; 127: 1404–1418. PubMed: https://pubmed.ncbi.nlm.nih.gov/32938299/
  22. Beddingfield B, Iwanaga N, Zheng W, Roy CJ, Hu TY, et al. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. JACC Basic Transl Sci. 2021; 6: 1-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/33102950/
  23. Mészáros B, Sámano-Sánchez H, Alvarado-Valverde J, Čalyševa J, Martínez-Pérez E, et al. Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications. Sci Signal. 2021; 14: eabd0334. PubMed: https://pubmed.ncbi.nlm.nih.gov/33436497/
  24. Zana X, Sitasuwana P, Powellb J, Dreherb TW, Wanga Q. Polyvalent display of RGD motifs on turnip yellow mosaic virus for enhanced stem cell adhesion and spreading. Acta Biomater. 2012; 8: 2978-2985. PubMed: https://pubmed.ncbi.nlm.nih.gov/22522012/
  25. Wang Y, Carrim N, Ni H. Fibronectin orchestrates thrombosis and hemostasis. Oncotarget. 2015; 6: 19350–19351. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637283/
  26. Vadasz B, Chen P, Yougbaré I, Zdravic D, Li J, et al. Article Feb 2015 Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia. Genes Dis. 2015; 2: 173-185. PubMed: https://pubmed.ncbi.nlm.nih.gov/28345015/

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Figure 1

Figure 10

Figure 1

Figure 11

Figure 1

Figure 12

Figure 1

Figure 13

Figure 1

Figure 14

Figure 1

Figure 15

Figure 1

Figure 16

Figure 1

Figure 17

Figure 1

Figure 18

Figure 1

Figure 19

Figure 1

Figure 20

Figure 1

Figure 21

Figure 1

Figure 22

Figure 1

Figure 23

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More